XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
  Asthma
  COPD
  Cystic Fibrosis
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
 
 India
Search

Last Updated: Nov 18, 2006 - 12:32:53 PM

COPD Channel
subscribe to COPD newsletter

Latest Research : Respiratory Medicine : COPD

   DISCUSS   |   EMAIL   |   PRINT
Combined treatment cuts inflammatory cells in chronic obstructive pulmonary disease
Apr 3, 2006 - 6:48:00 AM, Reviewed by: Dr. Sanjukta Acharya

"Inflammation in COPD is distinct from that in asthma and is characterized by a predominance of CD8+ cells at all airway levels, including the functional part of the lung, or parenchyma,"

 
The combination of two existing clinical treatments, salmeterol and fluticasone propionate, can significantly reduce inflammatory cells in the airways of current and former smokers being treated for moderate to severe chronic obstructive pulmonary disease (COPD).

Neil Barnes, M.D., Professor of Respiratory Medicine at London Chest Hospital in United Kingdom, and nine colleagues, performed a randomized, double-blind, placebo-controlled, parallel-group, multi-center study on 140 COPD patients. Of this total, 67 patients (average age 65) were treated with salmeterol/fluticasone propionate, while 73 individuals received a placebo medication. Both treatment groups were matched for demographics, smoking history, and baseline lung function.

"This is the first demonstration that a currently available treatment can reduce the exaggerated bronchial inflammation in COPD," said Dr. Barnes. He adds that this therapy decreased inflammation by 36 percent.

After conducting a biopsy examination, the researchers conclude that the combination therapy significantly reduced the absolute numbers of certain inflammatory cells, including leukocytes, CD8+ cells and CD4+ cells, and caused a reduction in cells expressing genes for certain pro-inflammatory mediators in the lung.

"Inflammation in COPD is distinct from that in asthma and is characterized by a predominance of CD8+ cells at all airway levels, including the functional part of the lung, or parenchyma," explained Dr. Barnes.

According to the authors, this broad spectrum of anti-inflammatory effects was also accompanied by a significant improvement in lung function.

"The magnitude of the improvement in the standard lung function test was similar to or greater than that seen in other studies of anti-inflammatory treatments used in COPD," said Dr. Barnes.

Using a bronchoscope, the investigators examined each participant's lung passages one week before the study began and after 12 weeks of treatment. Only four patients experienced adverse reactions to the bronchoscopy, such as nose bleed, cough, sore throat, etc.

The researchers gave six patients in the treatment group and eight in the control cohort an antibiotic to reduce worsening COPD symptoms. One patient from the treatment group also was hospitalized to treat worsening symptoms.

"As designed, our research represents the largest biopsy study ever to be completed in COPD," said Dr. Barnes.

He noted that these findings support the premise that the combination treatment could be applied earlier than currently proposed in existing COPD guidelines.
 

- These findings appear in the first issue for April 2006 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.
 

www.thoracic.org

 
Subscribe to COPD Newsletter
E-mail Address:

 



Related COPD News

COPD patients using beta-agonist inhalers are at risk
Beta-agonists more than double death rate in COPD patients
Lung function test underused in patients with COPD
Wrinkles clue to risk of progressive lung disease (COPD)
Antibiotics reduce risk of dying from COPD attack by 77 percent
Women with chronic obstructive pulmonary disease (COPD) fare worse than men
Breathing Heliox 28 significantly improve the exercise performance in COPD
Combined treatment cuts inflammatory cells in chronic obstructive pulmonary disease
COPD is slated to become world's biggest killer by 2020 - WHO
Study Shows Benefits of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us